INAB earnings analysis
What we found in INAB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
IN8bio, Inc. reported a net loss of $5.1 million for Q1 2026 compared to a net loss of $5.6 million in Q1 2025, demonstrating improved performance. There were no revenues reported, and management highlighted ongoing financial challenges but indicated progress in clinical developments related to its gamma-delta T cell therapies.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Net loss decreased to $5.1 million in Q1 2026 from $5.6 million in Q1 2025.
- Improved EPS
- Q1 2026 diluted EPS improved to -$0.26 compared to -$2.16 in the prior year.
- Increased Cash Reserves
- Cash increased to $21.9 million as of March 31, 2026.
- Decrease in Operating Expenses
- Total operating expenses fell to $5.3 million in Q1 2026 from $5.7 million in Q1 2025.
- Growth in Interest Income
- Interest income rose to $200,000 in Q1 2026 from $100,000 in Q1 2025.
- Clinical Trial Advances
- Management reported ongoing progress in Phase 1 trials and plans for an expansion cohort in the INB-100 trial.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going Concern Doubts
- There is substantial doubt about the company's ability to continue as a going concern, with cash expected to fund operations only through April 2027.
- Dependence on Clinical Trial Outcomes
- Future revenue is highly dependent on the success of ongoing clinical trials and obtaining regulatory approvals.
- Limited Revenue Generation
- The company has not generated any revenue since inception, raising concerns about long-term viability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.26
What they said about what is next.
Management expects to achieve meaningful clinical milestones.
The filing reads better than the one before it.
What came before.
- 10-K · March 12, 2026
- IN8bio, Inc. continues to struggle financially, reporting a net loss of $19.4 million for 2025, without generating any revenue. Management highlighted advancements in clinical trials but maintained a cautious approach…
- 10-Q · November 6, 2025
- INAB's Q3 2025 results show a continued absence of revenue, with net losses improving to $3.85 million from $7.09 million year-over-year. Operating expenses have decreased significantly, attributed to reduced research…
- 10-Q · August 7, 2025
- IN8bio, Inc. reported a net loss of $5.1 million for Q2 2025, a decrease from $8.7 million in Q2 2024, with no revenue recorded. The company continues to navigate challenges related to clinical trials, regulatory…
- 10-Q · May 7, 2025
- IN8bio reported its Q1 2025 results with no revenue, consistent with prior quarters, and an EPS of -$2.10, signifying an ongoing financial struggle. Operating expenses decreased from $8.6 million in Q1 2024 to $5.7…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INAB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever